TY - JOUR
T1 - Truncated SALL1 Impedes Primary Cilia Function in Townes-Brocks Syndrome
AU - Bozal-Basterra, Laura
AU - Martín-Ruíz, Itziar
AU - Pirone, Lucia
AU - Liang, Yinwen
AU - Sigurdsson, Jón Otti
AU - Gonzalez-Santamarta, Maria
AU - Giordano, Immacolata
AU - Gabicagogeascoa, Estibaliz
AU - de Luca, Angela
AU - Rodríguez, Jose A.
AU - Wilkie, Andrew O.M.
AU - Kohlhase, Jürgen
AU - Eastwood, Deborah
AU - Yale, Christopher
AU - Olsen, Jesper V.
AU - Rauchman, Michael
AU - Anderson, Kathryn V.
AU - Sutherland, James D.
AU - Barrio, Rosa
N1 - Funding Information:
We are grateful to the tissue donors and their families for their generosity. We thank M. Vivanco (CIC bioGUNE) for donating control tissue and C. Johnson and A. Magee for providing reagents. R.B. thanks the Spanish MINECO (BFU2014-52282-P and BFU2017-84653-P), the Severo Ochoa Excellence Accreditation (SEV-2016-0644), and Consolider Programs (BFU2014-57703-REDC). Support was provided by the Department of Industry, Tourism, and Trade of the Government of the Autonomous Community of the Basque Country (Etortek Research Programs) and by the Innovation Technology Department of the Bizkaia County. L.B.-B. thanks the Basque Government Department of Education for the fellowship PRE_2016_2_0226 and Boehringer Ingelheim for travel funding. J.A.R. is supported by funding from the Basque Government (IT634-13) and the University of the Basque Country UPV/EHU (UFI11/20). M.R. acknowledges support of the March of Dimes (6-FY13-127) and the National Institute of Diabetes and Digestive and Kidney Diseases(DK098563). We also thank the UPStream Consortium (ITN program PITN-GA-2011-290257, EU). Work at the Novo Nordisk Foundation Center for Protein Research is funded in part by a generous donation from the Novo Nordisk Foundation(NNF14CC0001).
Funding Information:
We are grateful to the tissue donors and their families for their generosity. We thank M. Vivanco (CIC bioGUNE) for donating control tissue and C. Johnson and A. Magee for providing reagents. R.B. thanks the Spanish MINECO ( BFU2014-52282-P and BFU2017-84653-P ), the Severo Ochoa Excellence Accreditation ( SEV-2016-0644 ), and Consolider Programs ( BFU2014-57703-REDC ). Support was provided by the Department of Industry, Tourism, and Trade of the Government of the Autonomous Community of the Basque Country (Etortek Research Programs) and by the Innovation Technology Department of the Bizkaia County. L.B.-B. thanks the Basque Government Department of Education for the fellowship PRE_2016_2_0226 and Boehringer Ingelheim for travel funding. J.A.R. is supported by funding from the Basque Government ( IT634-13 ) and the University of the Basque Country UPV/EHU ( UFI11/20 ). M.R. acknowledges support of the March of Dimes ( 6-FY13-127 ) and the National Institute of Diabetes and Digestive and Kidney Diseases ( DK098563 ). We also thank the UPStream Consortium (ITN program PITN-GA-2011-290257 , EU). Work at the Novo Nordisk Foundation Center for Protein Research is funded in part by a generous donation from the Novo Nordisk Foundation ( NNF14CC0001 ).
Publisher Copyright:
© 2017 The Author(s)
PY - 2018/2/1
Y1 - 2018/2/1
N2 - Townes-Brocks syndrome (TBS) is characterized by a spectrum of malformations in the digits, ears, and kidneys. These anomalies overlap those seen in a growing number of ciliopathies, which are genetic syndromes linked to defects in the formation or function of the primary cilia. TBS is caused by mutations in the gene encoding the transcriptional repressor SALL1 and is associated with the presence of a truncated protein that localizes to the cytoplasm. Here, we provide evidence that SALL1 mutations might cause TBS by means beyond its transcriptional capacity. By using proximity proteomics, we show that truncated SALL1 interacts with factors related to cilia function, including the negative regulators of ciliogenesis CCP110 and CEP97. This most likely contributes to more frequent cilia formation in TBS-derived fibroblasts, as well as in a CRISPR/Cas9-generated model cell line and in TBS-modeled mouse embryonic fibroblasts, than in wild-type controls. Furthermore, TBS-like cells show changes in cilia length and disassembly rates in combination with aberrant SHH signaling transduction. These findings support the hypothesis that aberrations in primary cilia and SHH signaling are contributing factors in TBS phenotypes, representing a paradigm shift in understanding TBS etiology. These results open possibilities for the treatment of TBS.
AB - Townes-Brocks syndrome (TBS) is characterized by a spectrum of malformations in the digits, ears, and kidneys. These anomalies overlap those seen in a growing number of ciliopathies, which are genetic syndromes linked to defects in the formation or function of the primary cilia. TBS is caused by mutations in the gene encoding the transcriptional repressor SALL1 and is associated with the presence of a truncated protein that localizes to the cytoplasm. Here, we provide evidence that SALL1 mutations might cause TBS by means beyond its transcriptional capacity. By using proximity proteomics, we show that truncated SALL1 interacts with factors related to cilia function, including the negative regulators of ciliogenesis CCP110 and CEP97. This most likely contributes to more frequent cilia formation in TBS-derived fibroblasts, as well as in a CRISPR/Cas9-generated model cell line and in TBS-modeled mouse embryonic fibroblasts, than in wild-type controls. Furthermore, TBS-like cells show changes in cilia length and disassembly rates in combination with aberrant SHH signaling transduction. These findings support the hypothesis that aberrations in primary cilia and SHH signaling are contributing factors in TBS phenotypes, representing a paradigm shift in understanding TBS etiology. These results open possibilities for the treatment of TBS.
KW - BioID
KW - SALL1
KW - Townes-Brocks syndrome
KW - primary cilia
KW - rare disease
KW - spalt
UR - http://www.scopus.com/inward/record.url?scp=85045398895&partnerID=8YFLogxK
U2 - 10.1016/j.ajhg.2017.12.017
DO - 10.1016/j.ajhg.2017.12.017
M3 - Article
C2 - 29395072
AN - SCOPUS:85045398895
SN - 0002-9297
VL - 102
SP - 249
EP - 265
JO - American Journal of Human Genetics
JF - American Journal of Human Genetics
IS - 2
ER -